DNA Repair Pathways and Human Metastatic Malignant Melanoma

被引:19
作者
Sarasin, A. [1 ]
Dessen, P. [1 ]
机构
[1] Univ Paris Sud, Inst Gustave Roussy, CNRS, Lab Genomes & Canc,FRE2939, F-94805 Villejuif, France
关键词
Melanoma; DNA repair; sun exposure; metastasis; cancer; NUCLEOTIDE EXCISION-REPAIR; GENETIC PREDISPOSITION; MISMATCH REPAIR; POLYMERASE-ETA; PHASE-II; CANCER; POLYMORPHISMS; EXPRESSION; CISPLATIN; RISK;
D O I
10.2174/156652410791317011
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Melanoma causes a considerable public health burden because of its dramatic rise in incidence worldwide since the mid-1960s and because the metastatic disease remains incurable, has a short median survival and is characterized by resistance to almost all classes of cytotoxic agents. DNA repair pathways are multiple and are able to repair, usually in an error-free manner, all kinds of DNA damage induced by exogenous and endogenous genotoxic agents. This review describes the role of DNA repair process in protecting us from cancer and particularly nucleotide excision deficiencies that are associated with melanoma development. Resistance of tumoral cells to antitumoral regimen can be caused by overexpression of DNA repair processes. We showed that melanoma metastasis was associated with higher expression of some DNA repair pathways leading to a better surveillance of replication fork fidelity. We showed a partially coordinated regulation of these repair genes. P53 and several transcription factors may regulate numerous of these repair genes. The repair pathways that are overexpressed in metastatic melanoma are those particularly efficient in repairing the major DNA damage produced by cytotoxic treatments. This implies that better analysis of DNA repair regulation is necessary to identify novel therapeutic targets and to allow clinicians to propose tailored therapies.
引用
收藏
页码:413 / 418
页数:6
相关论文
共 36 条
  • [1] Atkins MB, 2002, CLIN CANCER RES, V8, P3075
  • [2] Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system
    Balch, CM
    Soong, SJ
    Gershenwald, JE
    Thompson, JF
    Reintgen, DS
    Cascinelli, N
    Urist, M
    McMasters, KM
    Ross, MI
    Kirkwood, JM
    Atkins, MB
    Thompson, JA
    Coit, DG
    Byrd, D
    Desmond, R
    Zhang, YT
    Liu, PY
    Lyman, GH
    Morabito, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) : 3622 - 3634
  • [3] ERCC2/XPD gene polymorphisms and lung cancer:: A HuGE review
    Benhamou, S
    Sarasin, A
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2005, 161 (01) : 1 - 14
  • [4] Variability in nucleotide excision repair and cancer risk: a review
    Benhamou, S
    Sarasin, A
    [J]. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2000, 462 (2-3) : 149 - 158
  • [5] Human cancers express a mutator phenotype
    Bielas, Jason H.
    Loeb, Keith R.
    Rubin, Brian P.
    True, Lawrence D.
    Loeb, Lawrence A.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (48) : 18238 - 18242
  • [6] DNA repair pathways in drug resistance in melanoma
    Bradbury, PA
    Middleton, MR
    [J]. ANTI-CANCER DRUGS, 2004, 15 (05) : 421 - 426
  • [7] Molecular analysis of mutations in DNA polymerase η in xeroderma pigmentosum-variant patients
    Broughton, BC
    Cordonnier, A
    Kleijer, WJ
    Jaspers, NGJ
    Fawcett, H
    Raams, A
    Garritsen, VH
    Stary, A
    Avril, MF
    Boudsocq, F
    Masutani, C
    Hanaoka, F
    Fuchs, RP
    Sarasin, A
    Lehmann, AR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (02) : 815 - 820
  • [8] Malignant melanoma: genetics and therapeutics in the genomic era
    Chin, Lynda
    Garraway, Levi A.
    Fisher, David E.
    [J]. GENES & DEVELOPMENT, 2006, 20 (16) : 2149 - 2182
  • [9] FIGI A, 2009, MUTAT RES, V661, P78
  • [10] Fink D, 1996, CANCER RES, V56, P4881